Skip to main content

Dunne Michael W.'s Form 4/A amendment

Amended

Iterum Therapeutics plc (ITRM) · filed Feb 27, 2023

Accession no.
0001209191-23-013435
Filed
Feb 27, 2023
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Sep 9, 2022

This filing lists no transactions. It carries over 1 transaction from the original filing that it did not restate. Open-market purchases total $22.2K.

This amendment restates part of 0001209191-22-049352 (filed Sep 9, 2022). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dunne Michael W.CIK 0001553593Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0001209191-22-049352 (filed Sep 9, 2022).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0001209191-22-049352
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 7, 2022Ordinary SharesPPurchaseAcquired+10,000$2.22+$22,20035,576Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.

F2

This amendment is being filed to address an error due to rounding when calculating the reverse share split. The Amount of Securities Beneficially Owned Following Reported Transaction on September 7, 2022, which were reported as 35,576, should have been reported as 35,575. The extra share was also inadvertently included in the reporting person's Form 4 filed on January 4, 2023.

Read the full filing on SEC EDGAR (opens in a new tab)